Thalidomide treatment in a myelofibrosis patient with leukemia transformation

Wei Han Huang, Ming Shing Li, Sung Chao Chu, Tso Fu Wang, Ruey Ho Kao, Yi Feng Wu

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis. Leukemic transformation occurs in 8-23 % of myelofibrosis patients, and survival is about 3 months after transformation to leukemia. Thalidomide, an oral immunomodulatory drug, has been used effectively in the treatment of primary myelofibrosis, in which some patients could become transfusion independent, and showed improvement in thrombocytopenia and reduction in spleen size. Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. Thalidomide may be beneficial for some myelofibrosis patients with leukemic transformation for whom intensive chemotherapy is not indicated.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalInternational Journal of Hematology
Issue number2
Publication statusPublished - Feb 1 2014
Externally publishedYes


  • Acute leukemia
  • JAK2
  • Myelofibrosis
  • Thalidomide

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Thalidomide treatment in a myelofibrosis patient with leukemia transformation'. Together they form a unique fingerprint.

Cite this